Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,070,094
  • Shares Outstanding, K 159,688
  • Annual Sales, $ 616,290 K
  • Annual Income, $ 447,180 K
  • EBIT $ 123 M
  • EBITDA $ 121 M
  • 60-Month Beta 1.87
  • Price/Sales 8.29
  • Price/Cash Flow 11.41
  • Price/Book 7.83

Options Overview Details

View History
  • Implied Volatility 55.49% (-3.09%)
  • Historical Volatility 45.83%
  • IV Percentile 22%
  • IV Rank 20.93%
  • IV High 111.36% on 07/10/25
  • IV Low 40.70% on 01/21/26
  • Expected Move (DTE 17) 2.50 (7.93%)
  • Put/Call Vol Ratio 1.15
  • Today's Volume 1,107
  • Volume Avg (30-Day) 2,826
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 72,887
  • Open Int (30-Day) 68,084
  • Expected Range 29.01 to 34.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.25
  • Number of Estimates 4
  • High Estimate 0.35
  • Low Estimate 0.12
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +733.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.76 +17.75%
on 03/12/26
32.47 -2.96%
on 03/17/26
+1.42 (+4.72%)
since 02/27/26
3-Month
26.76 +17.75%
on 03/12/26
33.24 -5.20%
on 01/14/26
+0.74 (+2.40%)
since 12/26/25
52-Week
25.28 +24.64%
on 08/11/25
46.48 -32.21%
on 05/01/25
-8.35 (-20.95%)
since 03/28/25

Most Recent Stories

More News
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (“TG” or “the Company”), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured...

TGTX : 31.51 (-0.76%)
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - ...

TGTX : 31.51 (-0.76%)
DTIL : 5.42 (-9.97%)
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating...

TGTX : 31.51 (-0.76%)
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with...

TGTX : 31.51 (-0.76%)
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock – – Cash received supports Precision’s expected cash runway through...

TGTX : 31.51 (-0.76%)
DTIL : 5.42 (-9.97%)
TG Therapeutics: Q4 Earnings Snapshot

TG Therapeutics: Q4 Earnings Snapshot

TGTX : 31.51 (-0.76%)
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately...

TGTX : 31.51 (-0.76%)
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for...

TGTX : 31.51 (-0.76%)
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent...

TGTX : 31.51 (-0.76%)
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced a collaboration...

TGTX : 31.51 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 32.80
2nd Resistance Point 32.47
1st Resistance Point 31.99
Last Price 31.51
1st Support Level 31.18
2nd Support Level 30.84
3rd Support Level 30.36

See More

52-Week High 46.48
Fibonacci 61.8% 38.38
Fibonacci 50% 35.88
Fibonacci 38.2% 33.38
Last Price 31.51
52-Week Low 25.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.